Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Atrial fibrillation and anticoagulation in patients with breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Relationship Between Invasive Hemodynamics and Liver Function in Advanced Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Role of Pannexin and adenosine triphosphate (ATP) following myocardial ischemia/reperfusion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Socioeconomic position and one-year mortality risk among patients with heart failure: A nationwide register-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A prospective three-year follow-up study on the clinical significance of anti-neuronal antibodies in acute psychiatric disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Ischaemic heart disease, infection, and treatment of infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Objectives. To examine the long-term risk of thromboembolism and bleeding in patients with atrial fibrillation comparing patients with and without recent breast cancer in subgroups with or without anticoagulation therapy, respectively. Design. Using nationwide registries, patients with breast cancer from 1998-2015 and subsequent atrial fibrillation within 3 years were stratified on anticoagulation and matched 1:3 on age, sex and comorbidities with atrial fibrillation patients without breast cancer. Risks of thromboembolism and bleeding were estimated by Aalen-Johansen and multivariable cox regression models. Results. Atrial fibrillation patients with and without anticoagulation were matched, respectively (201 and 525 with breast cancer matched with 603 and 1,575 without breast cancer). In patients with CHA2DS2-VASc-score >1 and anticoagulation the three years risks of thromboembolism were 4.2% (95% confidence interval (CI) 1.1-7.3) and 3.2% (CI 1.5-4.9) in patients with and without breast cancer. The risks of bleeding were 5.3% (CI 1.7-8.9) and 5.1% (CI 3.0-7.1), respectively. Breast cancer was associated with a similar risk of thromboembolism in patients with and without anticoagulation, respectively (Hazard ratio (HR) 1.10, CI 0.63-1.92 and HR 1.11, CI 0.82-1.50) and a similar risk of bleeding in patients with and without anticoagulation, respectively (HR 1.01, CI 0.56-1.84 and HR 0.85, CI 0.57-1.27) compared with the matched controls. Conclusions. Breast cancer was not associated with altered risk of thromboembolism or bleeding in patients with atrial fibrillation irrespective of treatment with anticoagulation. Our analyses suggest that atrial fibrillation diagnosed in patients with breast cancer should be considered as primary atrial fibrillation.

OriginalsprogEngelsk
TidsskriftScandinavian cardiovascular journal : SCJ
Vol/bind53
Udgave nummer5
Sider (fra-til)247-254
Antal sider8
ISSN1401-7431
DOI
StatusUdgivet - 3 sep. 2019

ID: 57549241